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Abstract 
Background: The immunomodulatory agent pomalidomide in combination with low-dose dexamethasone has 
demonstrated efficacy and safety for the treatment of relapsed and refractory multiple myeloma (RRMM) in phase 2 
and 3 trials. However, these trials enrolled very few Asian patients.
Methods: This phase 2 study investigated pomalidomide plus low-dose dexamethasone in 36 Japanese patients 
with RRMM after ≥2 prior therapies.
Results: Patients enrolled in the study had a relatively high disease burden (81 % Durie–Salmon stage II or III) and 
were heavily pretreated (median, 6.5 prior antimyeloma regimens). The overall response rate was 42 % (1 patient with 
complete response and 14 with partial response), with an additional 44 % (16 patients) achieving stable disease (SD). 
Response rates in patients aged ≤65 years and >65 years were 47 and 35 %, respectively. None of the five patients 
with extramedullary disease achieved a response, with three of them maintaining SD of short duration. Median 
progression-free survival was 10.1 months after a 7.7-month median follow-up, and the median overall survival was 
not reached. The most frequent grade ≥3 adverse events (AEs) were neutropenia (64 %), anemia (42 %), and throm-
bocytopenia (31 %). The most frequent nonhematologic grade ≥3 AEs were pneumonia and decreased appetite (8 % 
each). Adverse events in patients aged >65 years were similar to those in patients aged ≤65 years, except for a higher 
rate of grade ≥3 pneumonia.
Conclusions: Collectively, the results of this study demonstrate that pomalidomide plus low-dose dexamethasone 
is an effective and safe treatment for Japanese patients with RRMM, although careful attention needs to be paid to 
serious infections.
Trial registration: Clinicaltrials.gov NCT02011113
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Background
Although the introduction of thalidomide, lenalidomide, 
and bortezomib has improved the survival of patients 
with multiple myeloma (MM) [1], MM remains incur-
able, and median overall survival (OS) for patients who 
have become refractory to bortezomib and thalidomide 
or lenalidomide is only 9 months [2]. Pomalidomide is a 
distinct IMiD® immunomodulatory compound with a 
mechanism of action that includes tumoricidal, immu-
nomodulatory, and antiangiogenic effects [3]. In combi-
nation with low-dose dexamethasone, pomalidomide was 
approved in the United States, Canada, and the European 
Union for the treatment of patients with relapsed and 
refractory MM (RRMM) who have received ≥2 prior 
therapies, including lenalidomide and bortezomib, and 
who have demonstrated disease progression on the last 
therapy (United States, Canada, European Union) or 
within 60 days of completion of the last therapy (United 
States) [4–6]. In addition, this regimen has recently been 
approved for the treatment of Japanese patients with 
RRMM.
In a North American phase 1/2 RRMM study (MM-
002), pomalidomide plus low-dose dexamethasone 
significantly extended progression-free survival (PFS) 
compared with pomalidomide alone [7, 8]. Furthermore, 
the regimen significantly improved both PFS and OS 
compared with high-dose dexamethasone alone in an 
international phase 3 trial (MM-003) [9]. The safety pro-
file of pomalidomide plus low-dose dexamethasone was 
acceptable in both studies [8, 9]. However, the number 
of Asian patients who were enrolled in these previous 
studies was very small. Additionally, there are no phase 
2 studies demonstrating the efficacy and safety profile of 
pomalidomide in Asian patients with RRMM.
Because pharmacokinetic (PK) and safety profiles of 
a drug can be affected by ethnicity [10–12], the phase 1 
MM-004 study evaluated the tolerated dose, PK, safety, 
and efficacy of pomalidomide, alone and in combination 
with low-dose dexamethasone, in Japanese patients with 
RRMM [13]. Pomalidomide 4 mg/day, the recommended 
dose in the United States, Canada, and European Union 
[4–6], was identified as the tolerated dose in this patient 
population [13], consistent with previous observations in 
Caucasian patients [7]. These results led us to the phase 
2 study, which investigated the efficacy and safety of 




A total of 36 patients were enrolled between December 
2013 and July 2014 at 13 sites in Japan; all patients were 
of Asian origin (Fig. 1). The median age was 64.5 years, 
and 11 % of the patients were aged >75 years (Table 1). 
The median time from first diagnosis was 4.7 years. Five 
patients (14 %) presented with extramedullary plasmacy-
toma in bone (n = 4) and liver (n = 1). Patients had a rela-
tively high disease burden, including Durie–Salmon stage 
II or III disease in 81 %, and were heavily pretreated, with 
a median of 6.5 prior antimyeloma regimens. All but 1 
patient (97 %) were refractory to lenalidomide, and 58 % 
were refractory to both lenalidomide and bortezomib.
Study treatment
Median treatment duration was 5.5  months (range, 
0.3–12.0 months), and the median number of treatment 
cycles was 6 (range, 1–13 cycles). At the data cutoff 
(February 3, 2015), 16 patients (44  %) remained on the 
protocol treatment. Disease progression was the most 
common reason for discontinuation (14 patients, 39 %). 
Three patients (8 %) discontinued because of an adverse 
event (AE), including 1 fatal AE of aggravated asthma 
and pneumonia, and three patients (8 %) discontinued for 
other reasons (Fig. 1).
Efficacy
All 36 patients received study treatment and were eval-
uable for efficacy. The overall response rate (ORR) was 
42 % (15 patients; 95 % CI, 26–58 %), with 1 patient (3 %) 
achieving a complete response (CR) and 14 patients 
(39  %) achieving a partial response (PR; Table  2). Sta-
ble disease (SD) was recorded as the best response in 
16 patients (44 %). Of these 36 evaluable patients, final 
pomalidomide doses at the last follow-up were 4  mg 
in 27 patiens, 3  mg in seven patients, and 2  mg in two 
patients with ORR of 44 % (12/27 patients, 1 CR and 11 
PRs), 43 % (3/7 patients, all PRs) and 0 % in each dose 
Fig. 1 Patient screening, enrollment, and follow-up in the trial
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group, respectively (Table  3). The median time to first 
response was 1.9  months, including 2 patients whose 
response improved from SD after ≥4 cycles of treatment 
(Fig.  2). The median duration of response (DOR) was 
not reached (95 % CI, 4.6 months-not estimable). After 
a median follow-up of 7.7 months, the median PFS was 
10.1 months (Fig. 3). A prespecified final OS analysis was 
conducted using a data cutoff of September 25, 2015; 
after median follow-up of 11.3  months, the 1-year OS 
was 58.5 %.
In patients aged ≤65 years, the ORR was 47 % (9/19 
patients, all PRs), and in patients aged >65  years, an 
ORR of 35  % was observed (6/17 patients, 1 CR and 5 
PRs). One of four patients aged >75 years achieved a PR. 
Analysis of impact of disease stage at the time of pro-
tocol enrollment showed that ORR in Durie–Salmon 
stage III disease (23 %) tended to be lower than that in 
stage I (57  %) or stage II (50  %) disease, although it is 
not statistically significant (P  =  0.28). ORR was 43  % 
among patients who were refractory to lenalidomide 
(15/35 patients, 1 CR and 14 PRs) and 33  % among 
those refractory to both lenalidomide and bortezomib 
(7/21 patients, all PRs). Recent studies have shown 
that thalidomide is effective in patients refractory to 
Table 1 Patient baseline characteristics
ECOG Eastern Cooperative Oncology Group




 Median (range), years 64.5 (43–78)
 >65 years, n (%) 17 (47.2)
 >75 years, n (%) 4 (11.1)
Sex, n (%)
 Male 16 (44.4)
 Female 20 (55.6)
Time from first diagnosis, median (range), years 4.7 (0.6–21.1)
ECOG performance status, n (%)
 0–1 33 (91.7)
 2 3 (8.3)
Durie–Salmon stage, n (%)
 I 7 (19.4)
 II 16 (44.4)
 III 13 (36.1)
β2-microglobulin level, n (%)
 <3.5 mg/L 24 (66.7)
 3.5–<5.5 mg/L 10 (27.8)
 ≥5.5 mg/L 2 (5.6)
Bone lesions, n (%) 22 (61.1)
Extramedullary plasmacytoma, n (%) 5 (13.9)
Creatinine clearance, n (%)
 <30 mL/min 0
 30–<45 mL/min 0
 45–<60 mL/min 8 (22.2)
 60–<80 mL/min 13 (36.1)
 ≥80 mL/min 15 (41.7)
Prior antimyeloma therapies, median (range) 6.5 (2–15)
Prior stem cell transplant, n (%) 19 (52.8)
Prior therapies, n (%)
 Lenalidomide 36 (100.0)
 Bortezomib 36 (100.0)
 Thalidomide 12 (33.3)
 Dexamethasone 35 (97.2)
 Melphalan 31 (86.1)
Last prior therapy, n (%)
 Lenalidomide 21 (58.3)
 Bortezomib 15 (41.7)
Refractory to prior therapies, n (%)
 Lenalidomide 35 (97.2)
 Bortezomib 21 (58.3)
 Both lenalidomide and bortezomib 21 (58.3)
Table 2 Responses based on IMWG criteria




Response rate, n (%)
 Overall response 15 (41.7)
  Complete response 1 (2.8)
  Very good partial response 0
  Partial response 14 (38.9)
 Stable disease 16 (44.4)
 Progressive disease 5 (13.9)
 Not evaluable 0
Time to response, median (range), months 1.9 (0.9–5.5)
Duration of response, median (range), months Not reached (1.9–11.1)
Table 3 Best response by final daily dose of pomalidomide
a Daily dose as of February 3, 2015
Variable Final daily dose of pomalidomidea
4 mg (n = 27) 3 mg (n = 7) 2 mg (n = 2)
Best response rate, n (%)
 Overall response 12 (44.4) 3 (42.9) 0
  Complete response 1 (3.7) 0 0
  Very good partial 
response
0 0 0
  Partial response 11 (40.7) 3 (42.9) 0
 Stable disease 11 (40.7) 3 (42.9) 2 (100)
 Progressive disease 4 (14.8) 1 (14.3) 0
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bortezomib and lenalidomide treatment [14, 15]. ORR 
among patients who had previously received thalido-
mide and those who did not receive thalidomide was 
33 % (4/12 patients, all PRs) and 46 % (11/24 patients, 
with 1 CR and 10 PRs), respectively, with no significant 
difference between two groups (P = 0.72), although the 
latter showed a trend toward longer PFS (3.3  months 
versus not reached, P  =  0.21). Median OS was not 
reached for patients who received or did not receive 
prior thalidomide. Of the five patients with plasmacy-
tomas, none achieved a response, with SD recorded as 
the best response in three patients. The median PFS for 
these five patients was 1.8 months.
Safety
All 36 patients reported ≥1 AE, and 31 patients (86  %) 
experienced a grade ≥3 AE, regardless of causality 
(Table 4). The most frequently reported grade ≥3 hema-
tologic AEs regardless of causality were neutropenia (23 
patients, 64  %), anemia (15 patients, 42  %), and throm-
bocytopenia (11 patients, 31  %). The most frequently 
reported grade ≥3 nonhematologic AEs regardless of cau-
sality were pneumonia (three patients, 8 %) and decreased 
appetite (three patients, 8  %). Other frequently reported 
AEs (any grade) were pyrexia (nine patients, 25 %); naso-
pharyngitis (eight patients, 22  %); and gastrointestinal 
disorders, including constipation (eight patients, 22  %), 
diarrhea, and nausea (seven patients, 19 % each).
Peripheral neuropathy (PN) of any grade occurred 
in three patients (8  %) and was considered to be treat-
ment-related in all cases. No occurrences of deep vein 
thrombosis or pulmonary embolism were reported; all 
patients received thromboprophylaxis, most commonly 
with aspirin (94  % of patients). Febrile neutropenia was 
observed in one patient (3 %), and severe infections and 
infestations occurred in three patients (8 %). Serious AEs 
were reported in 13 patients (36 %) and were considered 
treatment related in six patients (17 %). Constipation and 
Fig. 2 Treatment exposure and response duration of the enrolled 
patients. CR complete response, PD progressive disease, PR partial 
response, SD stable disease, VGPR very good partial response
Fig. 3 Kaplan–Meier estimates of progression-free survival from the start of first treatment to first documented disease progression or death, 
whichever occurred earlier, among patients who received pomalidomide plus low-dose dexamethasone in MM-011
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pneumonia were the only 2 treatment-related serious 
AEs that occurred in >1 patient (two patients, 6 % each).
Pomalidomide dosing was interrupted in 15 patients 
(42  %) and reduced in nine patients (25  %) due to AEs. 
AEs leading to dose reductions in >1 patient were 
thrombocytopenia (three patients, 8  %), anemia (two 
patients, 6 %), and leukopenia (two patients, 6 %). Three 
patients (8 %) had ≥1 AE that led to discontinuation of 
study treatment, all of which were considered treatment 
related. AEs leading to discontinuation were asthma, 
dyspnea, pleural effusion, anemia, pyrexia, and pneu-
monia. Nine patients (25 %) died during the study; eight 
deaths were due to progression of MM, and one was due 
to an AE of pneumonia and aggravated asthma that was 
suspected to be related to study treatment.
The AE profile in patients aged >65 years was broadly 
consistent with that in patients aged ≤65 years (Table 4), 
except for a higher rate of grade ≥3 pneumonia in the 
older patients.
Discussion
This study demonstrates that pomalidomide in com-
bination with low-dose dexamethasone is an effective 
regimen that confers disease stabilization or regression 
in 86  % of heavily pretreated Japanese patients with 
RRMM, with an acceptable safety profile consistent with 
the prior studies in other regions. The phase 3 MM-003 
trial, which was conducted in 93 centers in Europe, Rus-
sia, Australia, Canada, and the United States, previously 
investigated pomalidomide plus dexamethasone in 302 
patients with RRMM who had received prior therapy 
with both lenalidomide and bortezomib [9]. MM-003 
found that pomalidomide plus low-dose dexamethasone 
significantly improved PFS, OS, and ORR vs high-dose 
dexamethasone alone [9].
Due to the small sample size of MM-011, results may 
be less precise and the ability to compare with other tri-
als such as MM-003 is limited, therefore findings in our 
study should be interpreted with caution. However, the 
results reported here, including an ORR of 42  % (com-
pared with 31  % in MM-003), suggest that efficacy out-
comes of pomalidomide-based salvage treatment in 
RRMM could be more favorable depending on the cri-
teria used for patient selection [9]. It will be interesting 
to determine if, as in MM-003, patients with a greater 
response (either SD or ≥PR) experience a longer OS 
Table 4 Summary of  the most commonly reported adverse events (regardless of  causality and  reported at  any grade 
in ≥10 % of patients)
AE adverse event
n (%) All patients (N = 36) Age ≤65 years (n = 19) Age >65 years (n = 17)
All grades Grade ≥ 3 All grades Grade ≥ 3 All Grades Grade ≥ 3
Patients with ≥ 1 AE 36 (100.0) 31 (86.1) 19 (100.0) 16 (84.2) 17 (100.0) 15 (88.2)
Neutropenia 26 (72.2) 23 (63.9) 16 (84.2) 14 (73.7) 10 (58.8) 9 (52.9)
Anemia 17 (47.2) 15 (41.7) 9 (47.4) 8 (42.1) 8 (47.1) 7 (41.2)
Thrombocytopenia 17 (47.2) 11 (30.6) 11 (57.9) 6 (31.6) 6 (35.3) 5 (29.4)
Pyrexia 9 (25.0) 0 5 (26.3) 0 4 (23.5) 0
Constipation 8 (22.2) 2 (5.6) 6 (31.6) 1 (5.3) 2 (11.8) 1 (5.9)
Nasopharyngitis 8 (22.2) 0 2 (10.5) 0 6 (35.3) 0
Lymphopenia 7 (19.4) 6 (16.7) 4 (21.1) 3 (15.8) 3 (17.6) 3 (17.6)
Diarrhea 7 (19.4) 0 5 (26.3) 0 2 (11.8) 0
Nausea 7 (19.4) 0 4 (21.1) 0 3 (17.6) 0
Leukopenia 6 (16.7) 4 (11.1) 3 (15.8) 2 (10.5) 3 (17.6) 2 (11.8)
Peripheral edema 6 (16.7) 0 2 (10.5) 0 4 (23.5) 0
Rash 6 (16.7) 0 4 (21.1) 0 2 (11.8) 0
Insomnia 6 (16.7) 0 2 (10.5) 0 4 (23.5) 0
Pneumonia 5 (13.9) 3 (8.3) 1 (5.3) 0 4 (23.5) 3 (17.6)
Decreased appetite 5 (13.9) 3 (8.3) 2 (10.5) 1 (5.3) 3 (17.6) 2 (11.8)
Malaise 5 (13.9) 0 4 (21.1) 0 1 (5.9) 0
Dysgeusia 5 (13.9) 0 2 (10.5) 0 3 (17.6) 0
Hypoxia 4 (11.1) 1 (2.8) 3 (15.8) 1 (5.3) 1 (5.9) 0
Epistaxis 4 (11.1) 0 2 (10.5) 0 2 (11.8) 0
Upper respiratory tract infection 4 (11.1) 0 2 (10.5) 0 2 (11.8) 0
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compared with patients with progressive disease [16]. 
Additionally, median PFS in MM-011 was substantially 
longer than in the MM-003 trial (10.2 vs 4.0  months, 
respectively) [9], probably reflecting the differences in 
background characteristics of the patients participating 
in these studies.
One possible explanation for the observed differ-
ences in outcomes between MM-011 and MM-003 is the 
longer duration of treatment in MM-011 (median, 5.5 vs 
4.2  months) [9]. Subgroup analysis of MM-003 showed 
that some patients who achieved only SD within four 
cycles of treatment went on to improve their response 
status with continued treatment beyond four cycles [16]. 
Thus, the improved outcomes in MM-011 may reflect 
prolonged time on therapy.
Additionally, the observed differences in outcomes may 
reflect variability in disease characteristics between the 
patient population of MM-011 and the pomalidomide 
plus low-dose dexamethasone arm of MM-003. Several 
factors associated with poor outcomes were less com-
mon in MM-011 than in MM-003. For example, impaired 
renal function (creatinine clearance <60  mL/min) was 
present in 22  % of patients in MM-011 compared with 
31  % of patients in MM-003 [9]. Renal function may 
reflect the disease status of MM; however, preliminary 
data from the MM-008 study showed that pomalidomide 
dosing need not be reduced in patients with renal func-
tion impairment [17]. Additionally, slightly fewer patients 
in MM-011 had bone lesions compared with MM-003 
(61 vs 68 %) [9]. Advanced lytic lesions were reported to 
be a risk factor associated with poor survival in patients 
who receive pomalidomide [18]. Finally, patients had 
lower levels of serum β2-microglobulin in MM-011 vs 
MM-003 (Celgene Corporation, MM-003 clinical study 
report, unpublished observation). Higher serum β2-
microgloblin has been identified as a risk factor associ-
ated with shorter OS in patients refractory to bortezomib 
and IMiD immunomodulatory agents [2].
Of note, three out of five patients with plasmacytomas 
in MM-011 achieved SD following treatment with poma-
lidomide plus low-dose dexamethasone, albeit with a 
short median PFS of 1.8 months. Extramedullary disease 
associated with MM is known for poor prognosis, even 
after the introduction of novel agents, including lenalido-
mide and bortezomib, and thalidomide [19, 20]. There-
fore, improved treatment options are urgently needed for 
this patient population. Because pomalidomide has been 
shown to have more potent in vitro antimyeloma activity 
compared with conventional IMiD agents [21–23], fur-
ther studies are needed to determine whether pomalido-
mide plus low-dose dexamethasone provides a survival 
benefit in patients with extramedullary disease or non-
solitary plasmacytoma.
Use of prior treatment options also notably dif-
fered between MM-011 and MM-003. Fewer patients 
in MM-011 had received a prior stem cell transplant 
than patients in MM-003 (53 vs 71  %) [9]. Although 
patients had received a higher number of prior antimy-
eloma therapies in MM-011 vs MM-003 (median, 6.5 
vs 5 therapies), median time from initial diagnosis was 
shorter in MM-011 (4.7 vs 5.3 years). A similar propor-
tion of patients in MM-011 and MM-003 were refrac-
tory to lenalidomide (97.2 vs 95  %). Fewer patients in 
MM-011 were refractory to bortezomib alone (58 vs 
79  %) or to both lenalidomide and bortezomib (58 vs 
75 %). The lower levels of bortezomib refractory disease 
in MM-011 may result from differences in eligibility cri-
teria: MM-003, but not MM-011, included patients with 
primary refractory disease and required that patients 
had experienced prior treatment failure with both lena-
lidomide and bortezomib. These differences suggest that 
patients in MM-011 had disease that was not advanced 
as in MM-003, potentially accounting for the higher 
response rates and longer PFS observed. However, suba-
nalysis of MM-003 found no effect of prior treatment on 
response rate [16].
The chromosomal aberrations del(17p) and t(4;14) are 
associated with adverse prognosis, with median event-
free survival from diagnosis of only 20.6  months and 
15  months, respectively [24–27]. Therefore, the effi-
cacy of pomalidomide plus low-dose dexamethasone in 
MM-011 may have been affected by the proportion of 
patients with these poor-risk chromosomal aberrations. 
However, collection of data on chromosomal aberrations 
was not included in the MM-011 protocol, and this anal-
ysis is not available.
The non-hematologic AE profile in MM-011 was gen-
erally consistent with that of pomalidomide plus low-
dose dexamethasone treatment in MM-003, with a few 
exceptions. The incidence of severe infections was lower 
in MM-011 (8.3  % with grade ≥3 infection or infesta-
tion) than in MM-003 (30  % with grade 3/4 infection), 
as was the incidence of any grade febrile neutropenia (3 
vs 10 %) [9]. Venous thromboembolism (VTE) is associ-
ated with decreased survival in MM [28] and is a rare but 
potentially serious AE that has been reported with IMiD 
therapy [29, 30]. In a preliminary study in 1035 Japanese 
patients with MM treated with thalidomide, the inci-
dence of VTE was found to be lower than that in Western 
patients [31], potentially associated with genetic back-
ground and other factors related to ethnicity [32, 33]. In 
prior studies, appropriate thromboprophylaxis has been 
selected based on the risk of VTE for Japanese patients. 
With appropriate protocol-mandated thromboprophy-
laxis in MM-011, no cases of VTE were reported. Finally, 
PN is a common and potentially treatment-limiting AE 
Page 7 of 9Ichinohe et al. Exp Hematol Oncol  (2016) 5:11 
associated with thalidomide and bortezomib; however, 
pomalidomide as well as lenalidomide do not appear to 
cause substantial neurotoxicity [9, 34]. In MM-011, PN 
of any grade occurred in three patients (8 %) and did not 
lead to treatment discontinuation.
Grade ≥3 hematologic AEs occurred more frequently 
in MM-011 than in MM-003, including neutropenia (64 
vs 48 %), anemia (42 vs 33 %), and thrombocytopenia (31 
vs 22 %); however, the rate of all-grade hematologic AEs 
in MM-011 was similar to MM-003 [9]. In the Japanese 
MM-004 study, the incidence of grade ≥3 neutropenia 
was also higher than in MM-003 (67 vs 48 %) [9, 13]. This 
suggests that a greater number of Japanese patients may 
have a greater need for dose adjustments in response 
to hematologic AEs compared with those from other 
regions. The observed differences in AEs are not likely to 
be due to PK differences, as MM-004 found PK param-
eters of pomalidomide in Japanese patients with RRMM 
to be similar to those reported for pomalidomide in other 
RRMM populations, with limited accumulation after 
multiple doses [13]. Importantly, hematologic AEs were 
manageable with temporary discontinuation of treat-
ment or with concomitant administration of granulocyte 
colony-stimulating factor. The successful management of 
AEs may have contributed to extended duration of treat-
ment in MM-011.
Conclusions
In conclusion, pomalidomide 4  mg/day has been con-
firmed as the acceptable starting dose for Japanese 
patients, with dexamethasone administered at a dose 
of 40  mg/day (reduced to 20  mg/day for patients aged 
>75  years). Pomalidomide plus low-dose dexametha-
sone is a relatively safe and highly efficacious treatment 
for Japanese patients with RRMM who have previously 
received both lenalidomide and bortezomib. Patients 
who achieve stable disease or better response while on 
pomalidomide can continue to benefit from this therapy. 
Additional studies may be required to further define 




Eligible patients had documented MM and relapsed 
and refractory disease, defined as disease progression 
after ≥SD for ≥1 cycle of treatment or during or within 
60  days of completing treatment. Other inclusion crite-
ria were ≥2 prior therapies (including ≥2 cycles of lena-
lidomide and bortezomib, separately or in combination), 
age ≥20 years, and Eastern Cooperative Oncology Group 
performance status ≤2. Exclusion criteria included pre-
vious pomalidomide treatment; hypersensitivity to 
thalidomide, lenalidomide, or dexamethasone; abso-
lute neutrophil count <1000/μL; platelet count <75,000/
μL (or <30,000/μL if ≥50  % of bone marrow nucleated 
cells were plasma cells); creatinine clearance <45  mL/
min using the Cockcroft-Gault formula; corrected serum 
calcium >14  mg/dL (>3.5  mmol/L); hemoglobin <8  g/
dL (<4.9  mmol/L); liver enzyme concentrations >3.0× 
upper limit of normal (ULN); total bilirubin >2.0  mg/
dL (34.2  μmol/L; or ≥3.0× ULN for hereditary benign 
hyperbilirubinemia); congestive heart failure (New York 
Heart Association Class III/IV); myocardial infarction 
within 12  months; unstable or poorly controlled angina 
pectoris; and PN grade ≥2.
All patients provided informed consent; the study was 
approved by each study site’s institutional review board 
and was conducted in accordance with the Declaration 
of Helsinki and the International Conference on Harmo-
nisation guidelines on good clinical practice. The trial is 
registered as clinicaltrials.gov identifier NCT02011113.
Study design
MM-011 was a phase 2 multicenter, single-arm, open-
label study conducted in Japan (Fig. 1). Patients received 
pomalidomide (4 mg/day orally, days 1-21, 28-day cycles) 
and dexamethasone (40  mg/day [20  mg/day if aged 
>75  years] orally, days 1, 8, 15, and 22), consistent with 
United States and European Union approved dosing 
[4, 5]. Treatment was continued until disease progres-
sion, unacceptable toxicity, or withdrawal. All patients 
received thromboprophylaxis with low-dose aspirin, low-
molecular-weight heparin, or equivalent.
Pomalidomide was interrupted for grade 4 neutrope-
nia or thrombocytopenia, grade ≥3 constipation, VTE, 
rash, PN, or other pomalidomide-related AE, or grade 
≥2 hypothyroidism or hyperthyroidism. Additionally, 
pomalidomide was interrupted for febrile neutrope-
nia (any grade). Pomalidomide could be restarted at the 
same level or decreased by 1  mg. Discontinuation of 
pomalidomide was indicated for rash (grade 4 or blister-
ing) or grade ≥4 PN. Dexamethasone dose was modi-
fied for grade ≥3 edema, hyperglycemia, or any other 
dexamethasone-related AE. Additionally, dexamethasone 
was modified for grade ≥2 confusion/mood alteration or 
muscle weakness, or any grade dyspepsia. Dexametha-
sone was discontinued for acute pancreatitis.
The primary endpoint was response rate according to 
the International Myeloma Working Group (IMWG) cri-
teria [35]. Enrollment of 37 patients was planned using 
the expected response rate of 25 % based on the efficacy 
evaluable population, the threshold response rate of 10 %, 
on one-sided alpha of 0.05 and the statistical power of 
80  % based on the test for one sample proportion. Sec-
ondary endpoints included response rate according to 
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European Group for Blood and Marrow Transplantation 
(EBMT) criteria [36], time to response (TTR), DOR, PFS, 
and safety.
Efficacy assessments
Response was assessed by investigators using IMWG 
criteria and was confirmed by the members of an inde-
pendent response adjudication committee, who also 
confirmed responses using EBMT criteria. TTR was cal-
culated as the time from first dose to first documented 
response. DOR was defined as the time from first docu-
mented response to first documented disease progres-
sion. PFS was the time from first dose to first documented 
disease progression or death, whichever occurred earlier, 
and was estimated using the Kaplan–Meier method.
Safety evaluation
AEs were graded according to the National Cancer Insti-
tute Common Terminology Criteria for Adverse Events 
version 4.0 [37] throughout treatment and for 28  days 
after last dose. Other safety assessments included VTE 
monitoring, physical examinations, vital signs, electro-
cardiograms, and standard clinical laboratory assess-
ments (thyroid function, hematology, serum chemistry, 
urinalysis, creatinine clearance, and virology).
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